Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Vanda Pharmaceuticals Inc shares valued at $13,327 were purchased by Moran Kevin Patrick on Jul 29 ’24. At $5.92 per share, Moran Kevin Patrick acquired 2,251 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Moran Kevin Patrick sold 2,251 shares, netting a total of over 13,327 in proceeds. Following the sale of shares at $5.92 each, the insider now holds 228,763 shares.
Before that, Polymeropoulos Mihael Hristos had sold 24,288 shares from its account. In a trade valued at $100,273, the President and CEO traded Vanda Pharmaceuticals Inc shares for $4.13 each. Upon closing the transaction, the insider’s holdings decreased to 24,288 shares, worth approximately $9.94 million.
As published in their initiating research note from Cantor Fitzgerald on July 11, 2024, Vanda Pharmaceuticals Inc [VNDA] has been an Overweight and the price target has been revised to $11. Analysts at Jefferies downgraded the stock from ‘”a Buy”‘ to ‘”a Hold”‘ outlook in a report released in late February. As of May 12, 2021, BofA Securities has initiated its “Buy” rating for VNDA. Earlier on January 14, 2021, Citigroup downgraded its rating. Their new recommendation was “a Neutral” for VNDA stock which previously was a “a Buy”.
Analyzing VNDA Stock Performance
During the last five days, there has been a drop of approximately -5.85%. Over the course of the year, Vanda Pharmaceuticals Inc shares have jumped approximately 25.83%. Shares of the company reached a 52-week high of $6.75 on 06/13/24 and a 52-week low of $3.46 on 02/06/24. A 50-day SMA is recorded $5.76, while a 200-day SMA reached $4.59. Nevertheless, trading volume fell to 0.52 million shares from 0.48 million shares the previous day.
Support And Resistance Levels for Vanda Pharmaceuticals Inc (VNDA)
According to the 24-hour chart, there is a support level at 5.20, which, if violated, would cause prices to drop to 5.08. In the upper region, resistance lies at 5.39. The next price resistance is at 5.46. RSI (Relative Strength Index) is 37.92 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.51, which suggests the price will decrease in the coming days. Percent R is at 84.74%, indicating bearish price movement. Stochastics%K at buying indicates that the stock is to be held.
